Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding Ltd
(OP:
RHHVF
)
340.88
+6.45 (+1.93%)
Streaming Delayed Price
Updated: 12:45 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding Ltd
< Previous
1
2
3
4
5
6
7
Next >
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
January 23, 2024
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.
Via
MarketBeat
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
January 02, 2024
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.
Via
Benzinga
Exposures
COVID-19
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
December 11, 2023
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen...
Via
Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
December 05, 2023
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti
Via
Benzinga
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
December 04, 2023
Roche Holding AG (OTC: RHHBY) has agreed to
Via
Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...
Via
Benzinga
Exposures
Product Safety
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
October 19, 2023
Roche Holdings AG's (OTC: RHHBY) nine months
Via
Benzinga
Exposures
COVID-19
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
October 17, 2023
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:
Via
Benzinga
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
September 21, 2023
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
Via
Benzinga
Exposures
COVID-19
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,
Via
Benzinga
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
September 01, 2023
Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)...
Via
Benzinga
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
August 30, 2023
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme
Via
Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
August 23, 2023
Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t
Via
Benzinga
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs
Via
Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.
Via
Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
July 26, 2023
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen
Via
Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
July 24, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to
Via
Benzinga
Nvidia Invested $50 million into This AI Drug Discovery Biotech
July 17, 2023
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
July 14, 2023
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)
Via
Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
July 13, 2023
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...
Via
Benzinga
Agilent Technologies Stock: Ready to Rise off the Floor
June 21, 2023
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.
Via
MarketBeat
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
June 21, 2023
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next.
Via
MarketBeat
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma
June 16, 2023
The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)...
Via
Benzinga
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
June 09, 2023
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e
Via
Benzinga
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
May 17, 2023
Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)
Via
Benzinga
Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline
April 26, 2023
Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)
Via
Benzinga
FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma
April 20, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.